Role of chemotherapy in Hodgkin's lymphoma

Pamela Seam, John Edward Janik, Dan L. Longo, Vincent T. DeVita

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

The development of curative chemotherapy regimens for the treatment of Hodgkin's lymphoma (HL) is one of the true success stories in oncology. Most patients diagnosed with HL today can be cured. The major task remaining before us is curing as many patients as possible with their initial therapeutic approach while minimizing the acute toxicities and limiting the lifetime risks of important secondary events such as cardiovascular complications and secondary malignancies. In the 40 years since DeVita et al. developed the mechlorethamine, vincristine, procarbazine, and prednisone chemotherapy regimen, we have learned a great deal about risk stratification to minimize treatment-related toxicity. Positron emission tomography may further assist us in reducing radiation treatment without compromising cures. This review will discuss the development of the chemotherapy regimens used in the management of early and advanced stage HL and the advantages and disadvantages of their use in combination with radiation therapy.

Original languageEnglish (US)
Pages (from-to)150-154
Number of pages5
JournalCancer Journal
Volume15
Issue number2
DOIs
StatePublished - Mar 1 2009

Fingerprint

Hodgkin Disease
Drug Therapy
Procarbazine
Mechlorethamine
Vincristine
Therapeutics
Prednisone
Positron-Emission Tomography
Radiotherapy
Radiation
Neoplasms

Keywords

  • Antineoplastic agents
  • Combined modality therapy
  • Hodgkin's lymphoma
  • Positron emission tomography

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Seam, P., Janik, J. E., Longo, D. L., & DeVita, V. T. (2009). Role of chemotherapy in Hodgkin's lymphoma. Cancer Journal, 15(2), 150-154. https://doi.org/10.1097/PPO.0b013e3181a27018

Role of chemotherapy in Hodgkin's lymphoma. / Seam, Pamela; Janik, John Edward; Longo, Dan L.; DeVita, Vincent T.

In: Cancer Journal, Vol. 15, No. 2, 01.03.2009, p. 150-154.

Research output: Contribution to journalReview article

Seam, P, Janik, JE, Longo, DL & DeVita, VT 2009, 'Role of chemotherapy in Hodgkin's lymphoma', Cancer Journal, vol. 15, no. 2, pp. 150-154. https://doi.org/10.1097/PPO.0b013e3181a27018
Seam P, Janik JE, Longo DL, DeVita VT. Role of chemotherapy in Hodgkin's lymphoma. Cancer Journal. 2009 Mar 1;15(2):150-154. https://doi.org/10.1097/PPO.0b013e3181a27018
Seam, Pamela ; Janik, John Edward ; Longo, Dan L. ; DeVita, Vincent T. / Role of chemotherapy in Hodgkin's lymphoma. In: Cancer Journal. 2009 ; Vol. 15, No. 2. pp. 150-154.
@article{21772ecef99a4609b1d873673a407dd5,
title = "Role of chemotherapy in Hodgkin's lymphoma",
abstract = "The development of curative chemotherapy regimens for the treatment of Hodgkin's lymphoma (HL) is one of the true success stories in oncology. Most patients diagnosed with HL today can be cured. The major task remaining before us is curing as many patients as possible with their initial therapeutic approach while minimizing the acute toxicities and limiting the lifetime risks of important secondary events such as cardiovascular complications and secondary malignancies. In the 40 years since DeVita et al. developed the mechlorethamine, vincristine, procarbazine, and prednisone chemotherapy regimen, we have learned a great deal about risk stratification to minimize treatment-related toxicity. Positron emission tomography may further assist us in reducing radiation treatment without compromising cures. This review will discuss the development of the chemotherapy regimens used in the management of early and advanced stage HL and the advantages and disadvantages of their use in combination with radiation therapy.",
keywords = "Antineoplastic agents, Combined modality therapy, Hodgkin's lymphoma, Positron emission tomography",
author = "Pamela Seam and Janik, {John Edward} and Longo, {Dan L.} and DeVita, {Vincent T.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1097/PPO.0b013e3181a27018",
language = "English (US)",
volume = "15",
pages = "150--154",
journal = "Cancer Journal",
issn = "1528-9117",
number = "2",

}

TY - JOUR

T1 - Role of chemotherapy in Hodgkin's lymphoma

AU - Seam, Pamela

AU - Janik, John Edward

AU - Longo, Dan L.

AU - DeVita, Vincent T.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - The development of curative chemotherapy regimens for the treatment of Hodgkin's lymphoma (HL) is one of the true success stories in oncology. Most patients diagnosed with HL today can be cured. The major task remaining before us is curing as many patients as possible with their initial therapeutic approach while minimizing the acute toxicities and limiting the lifetime risks of important secondary events such as cardiovascular complications and secondary malignancies. In the 40 years since DeVita et al. developed the mechlorethamine, vincristine, procarbazine, and prednisone chemotherapy regimen, we have learned a great deal about risk stratification to minimize treatment-related toxicity. Positron emission tomography may further assist us in reducing radiation treatment without compromising cures. This review will discuss the development of the chemotherapy regimens used in the management of early and advanced stage HL and the advantages and disadvantages of their use in combination with radiation therapy.

AB - The development of curative chemotherapy regimens for the treatment of Hodgkin's lymphoma (HL) is one of the true success stories in oncology. Most patients diagnosed with HL today can be cured. The major task remaining before us is curing as many patients as possible with their initial therapeutic approach while minimizing the acute toxicities and limiting the lifetime risks of important secondary events such as cardiovascular complications and secondary malignancies. In the 40 years since DeVita et al. developed the mechlorethamine, vincristine, procarbazine, and prednisone chemotherapy regimen, we have learned a great deal about risk stratification to minimize treatment-related toxicity. Positron emission tomography may further assist us in reducing radiation treatment without compromising cures. This review will discuss the development of the chemotherapy regimens used in the management of early and advanced stage HL and the advantages and disadvantages of their use in combination with radiation therapy.

KW - Antineoplastic agents

KW - Combined modality therapy

KW - Hodgkin's lymphoma

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=67650095326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650095326&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e3181a27018

DO - 10.1097/PPO.0b013e3181a27018

M3 - Review article

VL - 15

SP - 150

EP - 154

JO - Cancer Journal

JF - Cancer Journal

SN - 1528-9117

IS - 2

ER -